Novartis’s Gilenya Loses Market Share After Safety Review

Novartis AG’s Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in the U.S.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.